SOTIO and Synaffix in ADC deal worth potential $740 million

The Lonza (SIX:LONN) subsidiary Synaffix, which is focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therapeutic index, has entered a licensing deal with SOTIO Biotech.

SOTIO, an immuno-oncology company owned by the Czech Republic's PPF Group, will gain access to Synaffix’ ADC technologies, GlycoConnect, HydraSpace and toxSYN linker-payloads, in an initial ADC program with the option to expand research and commercial licenses into two additional programs at a later date.

"This partnership can deliver innovative medicines for patients in areas of high unmet medical need"Synaffix will be eligible to receive up to $740 million in payments spanning signature, target nomination and milestone sums plus additional royalties on commercial sales.